

BMJ Best Practice

Meniere disease

Straight to the point of care



Table of Contents

Overview	3
Summary	3
Definition	3
Theory	4
Epidemiology	4
Etiology	4
Pathophysiology	4
Case history	5
Diagnosis	6
Approach	6
History and exam	7
Risk factors	8
Tests	10
Differentials	14
Criteria	16
Management	17
Approach	17
Treatment algorithm overview	21
Treatment algorithm	22
Patient discussions	30
Follow up	31
Monitoring	31
Complications	31
Prognosis	31
Guidelines	32
Diagnostic guidelines	32
Treatment guidelines	32
References	33
Images	43
Disclaimer	44

Summary

Meniere disease (MD) is an episodic auditory and vestibular disease characterized by sudden onset of vertigo, hearing loss, tinnitus, and sensation of fullness in the affected ear. Earlier in the disease process, all symptoms may not be present.

The cause is unknown, but results in an overproduction or impaired absorption of endolymph in the inner ear.

Diagnosis is made on clinical history and detailed audiology tests; other investigations may be required to exclude other causes.

Dietary changes and diuretics may control symptoms in early stages of the disease; specific medical therapies for vertigo control can be tried if required.

If symptoms persist despite maximal medical therapy, several surgical interventions are available.

Definition

Meniere disease or Meniere syndrome is an auditory disease characterized by an episodic sudden onset of vertigo, low-frequency hearing loss (in the early stages of the disorder), low-frequency roaring tinnitus, and sensation of fullness in the affected ear.^[1] Usually the terms are used interchangeably, but MD is commonly used if it is idiopathic and Meniere syndrome if it is secondary to a number of known inner-ear disorders.^[2]

It is also called endolymphatic hydrops, because of the described pathologic state observed on postmortem histologic sectioning.^[3] ^[4] It is unclear whether this is a cause of symptoms or a result of the pathologic process.

Epidemiology

The true incidence and prevalence of Meniere disease (MD) is not known. In a study from Rochester, Minnesota, the incidence was calculated as 15.30 per 100,000 people, with a prevalence of 218 per 100,000 population.[5] Data from South Korea report the incidence of MD in 2017 between 78.03 and 158.80 people per 100,000, in men and women respectively.[6]

MD is primarily a disease of adulthood, although several cases have been reported in children. Onset usually occurs in the fourth decade.[3] MD seems to have a higher prevalence in white people, and around 50% of patients have a family history of MD.[7] [8] MD is slightly more common in females, with a 2.17:1 female-to-male ratio.[6]

Incidence of bilateral disease varies in the literature between 2% and 73%.[9] [10] Other studies report that bilateral disease may occur in up to 50% of patients with MD during their lifetime.[3] [7] [11] More than 10% of people with apparent unilateral disease may be found to have bilateral disease on testing.[12]

Etiology

The underlying cause of meniere disease (MD) remains unknown. Some authors, however, believe that in up to 55% of cases, a specific etiologic agent can be identified.[13] [14] Among these etiologic agents are allergic responses (especially to food), congenital or acquired syphilis, Lyme disease, hypothyroidism, stenosis of the internal auditory canal, and acoustic or physical trauma.[13] Viral infection and immune-mediated mechanisms affecting the absorption of endolymph have also been implicated.[15] Hereditary factors are thought to play a role in the development of MD.[15] A multifactorial inheritance may be the best model, leading to endolymphatic malabsorption and subsequent hydrops.[15]

Pathophysiology

Endolymphatic hydrops is thought to be due to overproduction or impaired absorption of endolymph. This may occur as a result of one or a combination of the proposed etiologic agents. Some histopathologic studies of the temporal bones suggest that, although endolymphatic hydrops is a histologic marker for MD, it is not directly responsible for its symptoms.[16] However, studies from 2010 demonstrate through magnetic resonance imaging the central role of endolymphatic hydrops in the pathology of MD.[17]

During the acute attack the excessive endolymphatic fluid pressure causes distention and rupture of the Reissner membrane. This results in the release of potassium-rich endolymph into the perilymphatic space and causes injury to the sensory and neural elements of the inner ear, which manifests clinically as sudden hearing loss, tinnitus, and vertigo. Between attacks, the Reissner membrane may reattach itself, the chemical balance is restored, and symptoms remit.[3] However, some researchers are questioning this theory because membrane ruptures were found postmortem in temporal bones with no history of vertigo.[16]

Immune-mediated mechanisms have long been implicated in the pathophysiology of MD. This has been supported by the presence of increased levels of immune complexes and the presence of autoantibodies to structures of the inner ear in patients with MD. Lymphocytes and immunoglobulins have also been found in the endolymphatic sac.[18]

Case history

Case history #1

A 40-year-old woman presents with a 1-year history of recurrent episodes of vertigo. The vertigo spells are described as a sensation of the room spinning that lasts from 20 minutes to a few hours and may be associated with nausea and vomiting. The spells are incapacitating and are accompanied by dizziness, vertigo, and disequilibrium, which may last for days. No loss of consciousness is reported. The patient also reports aural fullness, tinnitus, and hearing loss in the right ear that is more pronounced around the time of her vertigo spells. Physical exam of the head and neck is normal. A horizontal nystagmus is noted. She is unable to maintain her position during Romberg testing or Fukuda stepping test. She turns toward the right side and is unable to walk tandem. Her cerebellar function tests are normal.

Other presentations

Patients may present with any combination of hearing loss, tinnitus, vertigo, or aural fullness.

Approach

Risk factors

Meniere disease (MD) usually presents in middle-aged people, with fluctuating auditory and vestibular symptoms. A family history of MD is present in up to 50% of patients. Patients with associated autoimmune disorders may have an autoimmune inner-ear disorder. These patients usually present with bilateral symptoms.^[20]

History

Classic MD has the triad of vertigo, hearing loss (HL), and tinnitus. Vertigo is unprovoked, sudden in onset, spinning in nature, and often incapacitating. It lasts minutes to hours and may be associated with nausea and vomiting.^[4] HL is usually worse during acute attacks, especially in early stages of the disease. As the disease progresses, HL increases in severity and may become constant. Tinnitus is described as roaring in nature and may be severe. Aural fullness is a sensation of pressure and fullness in the ear or ear discomfort and may also be present during the episode.

An atypical presentation of MD is fluctuating HL and tinnitus without vertigo. This is usually referred to as cochlear hydrops, and up to 40% of patients will eventually develop vertigo.^[22]

Some patients with MD complain of drop attacks, which are described as sudden loss of balance without loss of consciousness or other autonomic or neurologic symptoms. The incidence varies between studies and ranges between 3% to 10% of patients.^{[9] [23]} One study reported an unusually high incidence of 72%.^[24] They are more common in end-stage disease and in the older population.^[23]

Bilateral disease may be present in around 30% to 50% of patients.^{[3] [7] [11]}

Physical examination

Head and neck exam in patients with MD is usually normal. Horizontal and/or rotatory nystagmus that can be suppressed by visual fixation may be present. A positive Romberg test (inability to stand with feet together and eyes closed) and an inability to walk tandem (heel-to-toe) in a straight line is often present. In the Fukuda stepping test (also known as the Unterberger test) the patient is asked to march in place with eyes closed, and may be unable to maintain position and will turn toward the affected side.

Audiology

Complete audiologic evaluation is important for the diagnosis of MD and should be done in any patient presenting with HL, tinnitus, vertigo, or aural fullness. Complete audiologic evaluation includes pure-tone air and bone conduction with appropriate use of masking, speech audiometry, tympanometry, and otoacoustic emissions. Hearing loss in patients with MD is typically sensorineural in nature and mainly in the low frequencies, although other configurations of hearing losses may be present. Usually, low-frequency hearing loss is present in the early stages of MD and during or before attacks. As the disease progresses, middle and high frequencies are affected. There may be a disproportionate drop in word score recognition in comparison with pure-tone findings. Serial audiologic evaluation might show fluctuation in the hearing, which at times is helpful in making the diagnosis in patients with MD.

Once the diagnosis of MD is suspected, an electrocochleography (ECoChG) may be helpful. ECoChG is a technique for recording the electrical events of the cochlea. The clinical application is confined to the stimulus-related cochlear potentials and usually includes measurement of the entire nerve or compound

action potential of the auditory nerve. An ECochG consists of a cochlear microphonic and measures the cochlear summing potential and the action potential, independently or in combination. Broad-band clicks or tonal stimuli are used to evoke the components of interest.[25] [26] [27] [28] [29] ECochG should not be used when the pure-tone average for frequencies 1000-4000 Hz reaches or exceeds 50 dB HL. It does have value in the early stages of the disease when symptoms are present but audiometry is normal.[30] Once hearing is affected, the best serial test is pure-tone audiometry in the affected ear or ears. However, it is the author's opinion that the test should be performed at low frequencies down to 125 Hz.

Vestibular testing using electronystagmography or videonystagmography is performed routinely in patients presenting with vertigo, dizziness, or loss of balance. Rotatory chair or vestibular-evoked myogenic potentials are not available in all centers, but may be helpful in the diagnosis of MD. Vestibular testing may not be possible during or shortly after acute attacks.

Other investigations

Any patients with asymmetry of hearing should have magnetic resonance imaging (MRI) with gadolinium to exclude a retrocochlear cause of hearing loss, such as acoustic neuroma.

3-D MRI protocols have been developed to delineate endolymphatic hydrops, but they are still in the investigational stages.[31] MRI, after both intravenous and intratympanic injection of gadolinium, is being studied.[32] [33] [34]

Patients with MD who have bilateral symptoms and do not respond to conventional therapy should be tested for autoimmune disorders. This may include antinuclear antibody, antineutrophil cytoplasmic antibody, and rheumatoid factor.[35]

Patients with an acute or recent decrease in hearing should be assessed for hypothyroidism, Lyme disease, and syphilis.

History and exam

Key diagnostic factors

vertigo (common)

- Recurrent episodes of vertigo, described as a spinning sensation lasting minutes to hours. Usually associated with nausea and vomiting. Attacks tend to cluster in groups.

hearing loss (common)

- Usually fluctuating and worsens during or around the vertigo spells in initial stages.
- May become constant in later stages. Usually unilateral in the affected ear.

tinnitus (common)

- Usually described as roaring tinnitus. Usually unilateral in the affected ear.

aural fullness (common)

- Occurs in the affected ear.
- May increase before an attack.

drop attacks (uncommon)

- Sudden loss of balance without loss of consciousness or other autonomic or neurologic symptoms.
- More common in older people but can occur at any age.
- Tend to occur in late stages.

Other diagnostic factors**positive Romberg test (common)**

- Swaying or falling when asked to stand with feet together and eyes closed.

Fukuda stepping test (common)

- Turning toward the affected side when asked to march in place with eyes closed.

bilateral symptoms (uncommon)

- Autoimmune inner-ear disease is suspected in patients with bilateral meniere disease or history of other autoimmune systemic disorders.

nystagmus (uncommon)

- Horizontal and/or rotatory nystagmus that can be suppressed by visual fixation.
- Seen in acute attacks.

tandem walk (uncommon)

- Inability to walk (heel-to-toe) in a straight line.

Risk factors

Weak**recent viral infection**

- Viral infection with hematogenous spread, or direct spread through the round window membrane as a result of middle-ear infection or at the time of an upper respiratory tract infection, has been implicated in meniere disease (MD).[15]
- It is thought that viral infections cause inflammation in the inner ear and subsequently trigger a reactive immune response in the vicinity of the endolymphatic sac, causing damage to its function.
- Evidence of viral etiology is supported by demonstration of the presence of human cytomegalovirus by polymerase chain reaction in the endolymphatic sac tissues; antiviral immunoglobulin E in the sera of patients with MD; elevated anti-herpes simplex virus immunoglobulin G (IgG) in the perilymph of patients with MD; and higher titers of IgG against adenovirus and varicella zoster in patients when compared with controls.[19]

genetic predisposition

- There have been several reports in the literature about a genetic predisposition in meniere disease (MD). Hereditary factors have been found to play a role in 10% to 50% of cases.[15]
- The most commonly reported mode of inheritance is autosomal dominant pattern, but X-linked inheritance has also been reported.

- Higher frequency of histocompatibility antigen (HLA-DR, -DQ, and -DP) has been reported in patients with MD compared with controls.[15]

autoimmune disease


- Patients with associated autoimmune disorders such as vasculitis, rheumatoid arthritis, and lupus may have an autoimmune inner-ear disorder.[20] This is especially likely when meniere disease is bilateral at initial presentation.

increasing age

- Several studies indicate that prevalence and incidence rates increase with age, up to an age threshold of approximately 80 years.[6] [21] meniere disease is reported almost exclusively in adults, with peak onset occurring between ages 40 to 50 years.[8] [21]

Tests

1st test to order

Test	Result
<p>pure-tone air and bone conduction with masking</p> <ul style="list-style-type: none"> Pure-tone audiometry is the basic measurement of hearing sensitivity and the integrity of the entire auditory receptive pathway. Air-conduction thresholds are measured under headphones or with insert earphones. Bone measurements attempt to bypass the outer and middle ear and test the function of the cochlea and the auditory nerve. In MD (as well as in other cochlear disorders), air and bone conduction are equal, indicating that the underlying pathology is in the cochlea or auditory nerve, not the outer and the middle ear.  <p><i>Pure-tone audiometry typical of Meniere disease</i> From the collection of Maurice H. Miller, PhD</p>	<p>unilateral sensorineural hearing loss; usually low-frequency hearing loss is present in early stages of meniere disease (MD) and during or before attacks; as disease progresses, middle and high frequencies are affected</p>
<p>speech audiometry</p> <ul style="list-style-type: none"> Speech recognition threshold (SRT) measures the threshold (50% correct response) for a series of simple, everyday bisyllabic words such as airplane, baseball, and sidewalk. Discrepancies between SRT and pure-tone averages can suggest pseudohypacusis (nonorganic hearing loss) or a severe problem in word recognition ability (discrimination). Such discrepancies are not characteristic of meniere disease (MD). Word recognition score (WRS) measures the percentage of correct monosyllabic words, which are heavily loaded with high-frequency consonantal material (at increasing levels of intensity), above the SRT. WRS at multiple levels above the SRT is used to access the rollover phenomenon. The rollover ratio is calculated by subtracting the lowest speech discrimination score of phonetically balanced (PB) 	<p>no discrepancies on SRT, absence of positive rollover index</p>

Test	Result
<p>words (PB min) from the highest score (PB max) and dividing this figure by the PB max. A ratio ≥ 0.45 indicates a retrocochlear lesion. MD patients should not show a positive rollover index.[36]</p> <ul style="list-style-type: none"> Serial audiometry is helpful in making the diagnosis as well as a means of follow-up on the degree of hearing loss. 	
<p>tympanometry/immittance/stapedial reflex levels</p> <ul style="list-style-type: none"> Immittance evaluation including tympanometry stapedial reflex measurements (both ipsilateral and contralateral) and measurement of acoustic reflex decay. 	<p>normal tympanogram; elicitation of acoustic reflex <60 dB patient threshold; no abnormal reflex decay</p>
<p>otoacoustic emissions (OAE)</p> <ul style="list-style-type: none"> OAE are an electrophysiologic measure of outer hair cell dysfunction. Although measurable OAE is absent in the frequency range affected by meniere disease (MD), 18% of hydropic ears had unexpectedly present emissions even when the pure-tone thresholds were ≥ 50 dB.[37] Sounds produced by the cochlea are measured with a sensitive microphone in the ear canal, using a brief stimulus such as a click (transient-evoked OAE) or 2 stimulus tones of different frequency (distortion product OAE). These findings are not specific to MD but also apply to other cochlear disorders. OAE may also be affected by middle-ear disease. 	<p>absence of measurable OAE in frequency range affected by MD</p>

Other tests to consider

Test	Result
electrocochleography <ul style="list-style-type: none"> Measures electrical potentials that are derived from the hair cells in the cochlea and the auditory nerve. Should be repeated during the quiescent stage of the disease. 	abnormally large summing potential amplitude relative to the action potential amplitude
electronystagmography <ul style="list-style-type: none"> Records eye movements and responses to ocular and vestibular stimuli. A unilateral decreased vestibular response in the affected ear suggests peripheral etiology, such as vestibular neuronitis.[38] Caloric response diminishes with increased disease duration, and a canal paresis of 35% to 50% is commonly observed in the affected ear.[9] Great care should be exercised in performing vestibular testing when the patient is having an acute attack of meniere's disease (MD). Some vestibular evaluation procedures may precipitate an acute attack and should be avoided if not necessary for diagnosis. 	abnormal in MD; unilateral decreased vestibular response in the affected ear is common
rotary chair test <ul style="list-style-type: none"> Sinusoidal harmonic acceleration or rotating chair testing involves a variety of measurements of nystagmus on a patient who is rotated from side to side during the procedure in a computer-controlled chair. 	decreased gain, abnormal phase, and asymmetry in the response
vestibular-evoked myogenic potential (VEMP) <ul style="list-style-type: none"> VEMP uses an intense, brief auditory stimulus to assess the saccule ipsilateral to the stimulus. VEMP is not approved by the Food and Drug Administration. 	increased amplitude in early disease; attenuated or absent in later stages
MRI of internal auditory canals <ul style="list-style-type: none"> Any patient with unilateral, sudden, or asymmetric sensorineural hearing loss should have MRI with gadolinium to exclude a retrocochlear cause of hearing loss (such as acoustic neuroma). 	normal in meniere disease
thyroid function tests <ul style="list-style-type: none"> Elevated thyroid-stimulating hormone and low thyroxine if hypothyroidism is cause of hearing loss. 	normal in meniere disease
Lyme disease and syphilis serology <ul style="list-style-type: none"> Positive titers suggest these conditions are the cause of acute or recent deterioration in hearing. 	normal in meniere disease
antinuclear antibody <ul style="list-style-type: none"> High sensitivity, but low specificity for systemic lupus erythematosus.[35] 	negative in most cases; positive titer in the presence of associated autoimmune pathology
antineutrophil cytoplasmic antibody <ul style="list-style-type: none"> Associated with vasculitis. 	negative in most cases; positive titer in the presence of associated autoimmune pathology
rheumatoid factor <ul style="list-style-type: none"> Sensitive, but nonspecific for rheumatoid arthritis.[35] 	negative in most cases; positive titer in the

Test	Result
	presence of associated autoimmune pathology

Emerging tests

Test	Result
3-dimensional MRI <ul style="list-style-type: none">3-D MRI protocols have been developed to delineate endolymphatic hydrops, but they are still in the investigational stages. MRI, after both intravenous and intratympanic injection of gadolinium, is being studied.[32] [33] [34]	perilymphatic space surrounding the endolymph is either small or unable to be visualized

Differentials

Condition	Differentiating signs / symptoms	Differentiating tests
Acoustic neuroma	<ul style="list-style-type: none"> • Small acoustic tumors typically present as unilateral high-frequency hearing loss with difficulty hearing on the telephone on affected ear. • Acoustic neuroma should be ruled out in any unilateral sensorineural hearing and therefore in patients with meniere disease.[39] 	<ul style="list-style-type: none"> • There is reduced word recognition to an inordinate degree when compared with pure-tone air and bone conduction testing (phonemic regression), rollover phenomenon, absent or elevated acoustic reflexes, abnormal findings on stapedial reflex decay, and abnormal auditory brainstem response. • Hearing tests may be within normal limits in patients with small acoustic neuromas. • MRI with gadolinium contrast will show a tumor involving the acoustic nerve.
Vestibular migraine (also called migraine-associated dizziness and migraine-associated vertigo)	<ul style="list-style-type: none"> • Incidence of migraine is significantly greater in populations of meniere disease (MD) patients, and incidence of complaints of dizziness and MD is greater in migraine populations, than the incidence of either in the general unselected population.[40] • Symptoms and clinical test findings produced by both disorders overlap, and both conditions can coexist in the same patient. • A very short (<15 minutes) or prolonged (>24 hours) duration of vertigo suggests migraine, and visual auras are more likely. Hearing loss is usually mild and stable over time. 	<ul style="list-style-type: none"> • Investigations are variable and nonspecific. Diagnosis is made on clinical history.[40]
Vestibular neuronitis	<ul style="list-style-type: none"> • Neural degeneration or viral infection of the eighth nerve can produce acute or chronic vertigo, nausea, and vomiting. There is no hearing loss, tinnitus, or aural fullness. • Occurs in epidemics and is most common in people between 40 and 50 years 	<ul style="list-style-type: none"> • Electronystagmography (particularly using bithermal caloric testing) often shows unilateral weakness on the affected side, but may be normal.

Condition	Differentiating signs / Differentiating tests symptoms	
	<p>of age. Frequently, patients have had a recent viral infection.</p> <ul style="list-style-type: none"> Attacks are of precipitous onset, often occurring at night. Severe rotational vertigo lasts 12 to 36 hours with decreasing disequilibrium for the next 4 to 5 days. 	
Viral labyrinthitis	<ul style="list-style-type: none"> Similar presentation to vestibular neuronitis but accompanied by hearing loss and tinnitus.[41] 	<ul style="list-style-type: none"> Patients show various degrees of hearing loss on complete audiologic evaluation.
Benign paroxysmal positional vertigo (BPPV)	<ul style="list-style-type: none"> Patients typically present with episodic vertigo lasting in the range of a few seconds to a minute elicited by certain head movements. These movements include lying flat with the neck extended and turned toward the affected ear, neck extension, and bending over. Unlike attacks caused by meniere disease (MD), the vertigo spells are not associated with hearing loss, tinnitus, or aural fullness. The vertigo could recur over a period of weeks to months and may resolve spontaneously. Patients usually report a history of trauma or vestibular neuritis. It is important to note that BPPV and MD have been reported to coexist in the same patient.[42] 	<ul style="list-style-type: none"> Hallpike test will show rotatory nystagmus on the affected side. This is performed by starting in the sitting position then bringing to a supine position with the head turned 45° toward one side with 20° neck extension. Patients with BPPV usually demonstrate a short-lasting torsional nystagmus in this position.[43]
Vertebrobasilar insufficiency	<ul style="list-style-type: none"> Cerebrovascular disease is more common in older people. The vertigo might be secondary to ischemia of the labyrinth, brainstem, or both, because they are all supplied by the vertebrobasilar circulation.[44] Vertigo spells usually last for several minutes, and are accompanied by nausea, vomiting, and severe imbalance. Associated symptoms may include 	<ul style="list-style-type: none"> Carotid duplex ultrasound may show changes of atherosclerosis, which implies changes in the cerebral circulation. CT head may show evidence of previous cerebral infarction. Magnetic resonance angiography of vessels of neck, base of skull, and circle of Willis may be abnormal.

Condition	Differentiating signs / symptoms	Differentiating tests
	visual blurring or blackouts, diplopia, drop attacks, weakness and numbness of the extremities, and headache.[44]	

Criteria

Diagnostic criteria for Menière's disease: Classification Committee of the Bárány Society, Japan Society for Equilibrium Research, European Academy of Otolaryngology and Neurotology (EAONO), Equilibrium Committee of the American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS), Korean Balance Society[45]

Definite meniere disease (MD)

- Two or more spontaneous episodes of vertigo, each lasting 20 minutes to 12 hours
- Audiometrically documented low- to medium-frequency sensorineural hearing loss in one ear, defining the affected ear on at least one occasion before, during, or after one of the episodes of vertigo
- Fluctuating aural symptoms (hearing, tinnitus, or fullness) in the affected ear
- Not better accounted for by another vestibular diagnosis.

Probable MD

- Two or more episodes of vertigo or dizziness, each lasting 20 minutes to 24 hours
- Fluctuating aural symptoms (hearing, tinnitus, or fullness) in the affected ear
- Not better accounted for by another vestibular diagnosis.

Ten-point scale for the clinical diagnosis of MD[12]

Based on clinical history. One point awarded to each of the following. The closer the score is to 10, the more likely the patient is to have MD.

- Rotational vertigo
- Attacks of vertigo lasting >10 minutes
- Rotational vertigo associated with 1 or more of hearing loss, tinnitus, or aural pressure
- Sensorineural hearing loss
- Fluctuating hearing loss
- Hearing loss or fluctuation associated with vertigo, tinnitus, or aural pressure
- Peripheral tinnitus lasting >5 minutes
- Tinnitus fluctuating or changing with 1 or more of the following: vertigo, hearing loss, or aural pressure
- Aural pressure/fullness lasting >5 minutes
- Aural pressure fluctuating or changing with vertigo, hearing loss, or tinnitus.

Approach

There is no cure for meniere disease (MD). The goals of treatment are vertigo control, prevention of further deterioration in hearing whenever possible, amelioration of tinnitus, and balance control. Treatment options, however, do not appear to influence hearing results or the natural history of MD.[48]

Endolymphatic hydrops has been implicated in the pathophysiology or pathogenesis of MD and, therefore, the management of patients with MD has traditionally been targeted toward decreasing endolymphatic pressure. This has been questioned by a study suggesting that such measures aiming at reduction in hydrops would be unlikely to control the disease. Some histopathologic studies of the temporal bones suggest that, although endolymphatic hydrops is a histologic marker for MD, it is not directly responsible for its symptoms.[16] However, studies from 2010 demonstrate through magnetic resonance imaging the central role of endolymphatic hydrops in the pathology of MD.[17] It is important to note that MD presents a research controversy in evaluating the efficacy of different therapies.[49] [50] [51]

Dietary changes and lifestyle modification

All patients should be educated on dietary changes and lifestyle modification. Patients should be advised to restrict salt intake to 1500 to 2300 mg/day, as this is thought to prevent sodium-related water retention and redistribution into the endolymphatic system.[21] [52] Although there are no randomized controlled trials (RCTs) to document the benefits of low-salt diet on the treatment of MD, patients often report exacerbation of their symptoms or even precipitation of an attack after a salty meal.[52] [53]

Limiting caffeine intake, reducing alcohol consumption, ceasing smoking, and managing stress are also advisable, as these may trigger an attack. However, there is no evidence from RCTs to support or refute the restriction of salt, caffeine, or alcohol intake in patients with MD.[53] [54]

Such dietary changes may be the only necessary treatment required in the early stages of the disease.

Medical therapy to decrease endolymphatic pressure

Diuretics are believed to reduce the volume of the endolymph and may be offered for maintenance therapy.[21] [55] The most commonly used diuretics in the treatment of MD are thiazides-with or without potassium-sparing diuretics (e.g., hydrochlorothiazide/triamterene)-and acetazolamide.[21] Thiazide diuretics are thought to act on the sodium/potassium adenosine triphosphatase levels in the stria vascularis in cochlear tissues and to have an effect on the maintenance of endolymph homeostasis.[56] Acetazolamide is thought to act on carbonic anhydrase in dark cells and in the stria vascularis.[52] If the patient remains symptom-free for 6 months, diuretics may be slowly tapered and restarted if required. If there is no response, the patient should be changed to the alternative diuretic. These medications should not be used in patients with a known or suspected reaction to sulfonamides.

The evidence of the efficacy of diuretics on MD is controversial, and direct evidence of its efficacy on disease progression is lacking in the literature.[2] However, diuretics are still considered by many physicians to be first-line treatment in patients with MD.

Symptomatic treatments

Vertigo

Symptoms of individual and acute vertigo spells can be treated with vestibular suppressants and antiemetics. However, much of the effect is from the sedative action of these drugs. The literature

lacks RCTs assessing the effects of these medications for acute attacks of MD. Commonly used treatments include antihistamines (e.g., meclizine, dimenhydrinate, promethazine), benzodiazepines (e.g., diazepam), and phenothiazines (e.g., prochlorperazine).[57] Diazepam should only be used in acute attacks.[21] It should be prescribed at low doses where possible, and long-term prescription avoided due to the risk of dependency. Anticholinergics (e.g., scopolamine and atropine) are not commonly prescribed due to their significant side-effect profile.[21]

Betahistine is used in some countries to reduce the frequency and severity of the vertigo attacks in patients with MD. However, one Cochrane review did not find enough evidence to show its efficacy in patients with MD and one 2016 RCT found no significant differences in the mean attack rate compared with placebo.[58] [59] Betahistine is not approved in the US; however, it may be compounded if necessary.[58] [59]

Corticosteroids, whether used orally or as intratympanic injections, may be used to treat acute attacks of vertigo, especially when accompanied by acute hearing loss and tinnitus. They are widely used because of their anti-inflammatory properties, although no RCTs are available to assess their efficacy in MD.[60]

Tinnitus

Patients with severe, intractable tinnitus can receive relief with a number of modalities, such as tinnitus maskers, tinnitus retraining therapy (TRT), various forms of sound-based therapies such as neuromonics phase-shift tinnitus reduction, amplifications, medication, and biofeedback. Tinnitus questionnaires are helpful in evaluating the severity of the problem and in documenting the effects of various treatment modalities.[61] [62] [63]

Tinnitus maskers (white noise generators) are devices similar to hearing aids that fit behind or in the ear. They produce an external sound that distracts the patient from the internal tinnitus noise.

TRT is counseling accompanied by white noise generators. TRT is a favored treatment, but it may take up to 18 months before full benefits are achieved.[64] [65]

Amplification (hearing aids) may help in masking the tinnitus and achieving residual inhibition.

Biofeedback techniques attempt to decrease the anxiety that is associated with tinnitus. This can be achieved through relaxation techniques, hypnosis, and cognitive behavioral therapy.

Neuromonics uses a customized neural stimulus combined with specific music, delivered through a coordinated program to interact with, interrupt, and desensitize tinnitus disturbance for long-term benefit.[66] [67] [68]

Medications such as antidepressants (e.g., amitriptyline) and benzodiazepines (e.g., alprazolam) may help patients with intractable tinnitus, but are associated with adverse effects.[69] They should only be used if the above techniques are unsuccessful and debilitating tinnitus persists.

Hearing loss

Sudden hearing loss is treated with corticosteroids (either orally or intratympanically).

Amplification using fully digital hearing aids with variable digitally adjustable circuitry should be evaluated. The traditional view that amplification does not work for patients with MD is not based on experience with modern amplification.

New forms of directional microphones, digital signal processing circuitry, and wireless technology can provide significant benefits in helping MD patients to hear better in environments with competing noise.[70]

Assistive listening devices are a form of amplification for those with situational difficulties in hearing, and who are not yet ready or willing to use personal hearing aids.

Intensive high-quality audiologic counseling is needed for patients with MD in the adjustment to, and acceptance of, amplification.

Intratympanic therapy

In intratympanic therapy, medications are injected into the middle ear and are then absorbed through the round window into the fluid system of the inner ear. This allows targeting of the inner-ear system without exposing the body to the systemic adverse effects of the medication in use.

Two agents can be used intratympanically in patients with MD, depending on the presenting symptoms. Intratympanic corticosteroids are more commonly used in patients with MD presenting with sudden onset of hearing loss. Intratympanic gentamicin (an aminoglycoside antibiotic) injections are helpful in the treatment of intractable vertigo.

Intratympanic corticosteroid injections (e.g., dexamethasone or methylprednisolone) are used in patients with MD where systemic corticosteroids are contraindicated, or in patients who do not respond to oral corticosteroids. One double-blind, RCT found no significant difference between intratympanic gentamicin and intratympanic methylprednisolone at controlling attacks of vertigo in patients with refractory, unilateral MD.[71] The reported success rate of intratympanic corticosteroids in other studies has been variable.[60] [72] [73] [74]

When injected into the middle ear, gentamicin preferentially destroys the vestibular labyrinth. This results in chemical labyrinthectomy and is an alternative to surgical labyrinthectomy in patients with intractable vertigo. Hearing loss can be minimized by meticulously titrating the dose of gentamicin to vertigo control, stopping therapy at the earliest signs of hearing loss, and following up closely with repeated hearing tests. This approach has been found to result in complete (81.7%) and effective (96.3%) vertigo control.[75] One meta-analysis on gentamicin injections found complete vertigo control in about 75% of the patients and complete or substantial control in about 93%.[76] Hearing level and word recognition did not deteriorate with treatment. None of the trials were double-blind or had a blinded, prospective control, and therefore the level of evidence was insufficient.[76] Overall hearing loss, as a complication of gentamicin injection, has been found in 25% of patients, with a range of 13.1% to 34.7%. In a prospective, double-blind, randomized, placebo-controlled clinical trial, intratympanic gentamicin treatment was found to reduce the score of vertigo severity and perceived aural fullness in the treatment group.[77] Evidence suggests that intratympanic gentamicin injections improve vertigo symptoms, are well tolerated, and have a low incidence of severe hearing loss.[21] However, two systematic reviews in 2023 found that evidence for the use of intratympanic gentamicin and corticosteroid injections in the treatment of patients with MD is uncertain.[78] [79]

Meniett device

The Meniett device is a handheld device that delivers intermittent pressure pulses through the ear canal and is self-administered 3 times per day. A tympanostomy tube is placed in the tympanic membrane and should be kept patent throughout the treatment. It is thought that the pressure treatment induces

longitudinal movement of endolymph and improves the hydropic condition. Evidence for the Meniett device for use in MD appears to be mixed. Initial RCTs have shown that the use of the Meniett device significantly reduced vertigo frequency in two-thirds of the patients and that the improvement was maintained long term.[80] Furthermore, no serious adverse effects have been reported in the trials.[81] In contrast, systematic reviews assessing the effectiveness of positive pressure therapy devices (including the Meniett device or similar) have failed to show any benefit of these devices in improving the symptoms of MD.[82] [83] The American Academy of Otolaryngology 2020 guidelines recommend against the use of positive pressure therapy in patients with MD.[21]

Surgical therapy

The surgical management of patients with MD has changed as a result of the introduction of less invasive office procedures, including intratympanic therapy and the Meniett device.

Surgical approaches are used in patients with intractable vertigo who are refractory to medical therapy. The choice between these procedures depends on the severity of the vertigo spells, degree of serviceable hearing, age and physical condition of the patient, condition of the opposite ear, and the patient's choice.

Surgical procedures are divided into nondestructive procedures that reverse the pathophysiologic hydrops and preserve hearing, such as endolymphatic sac surgery (ELS), and destructive procedures that abolish the vestibular response either by destroying the inner ear (as in labyrinthectomy) or by cutting the vestibular nerve (as in vestibular neurectomy).

ELS is a procedure that consists of decompression of the endolymphatic sac from the overlying bone and drainage of its endolymph. Its role in MD is controversial, with studies that show 90% resolution of vertigo, and others that demonstrate it is no more effective than placebo, or that there is insufficient evidence of the beneficial effect of ELS in MD.[7] [84] [85] [86][87] [88] [89] A recent systematic literature search and meta-analysis revealed a paucity of studies on this surgical procedure, indicating ELS may be a beneficial treatment for patients with MD.[89] However, further studies are needed to attain a better understanding of the efficacy of ELS for treating MD.

Labyrinthectomy results in loss of residual hearing and therefore is indicated in patients who have no serviceable hearing. Vestibular nerve section is aimed at preserving residual hearing and is therefore a choice in patients with serviceable hearing.

Vestibular and balance rehabilitation therapy

Vestibular and balance rehabilitation therapy is recommended for patients who have problems with balance.[90] [91] Originally, patients considered for vestibular therapy were the ones who had relief from vertigo by destructive surgery or intratympanic gentamicin injections but who complained of persistent disequilibrium. It has been reported that patients whose vertigo is controlled by medical therapy or intratympanic corticosteroid injections and who complain of disequilibrium may benefit from vestibular therapy.[92] Vestibular therapy should not be recommended to patients with MD experiencing acute vertigo attacks.[21]

Treatment algorithm overview

Please note that formulations/routes and doses may differ between drug names and brands, drug formularies, or locations. Treatment recommendations are specific to patient groups: [see disclaimer](#)

Acute (summary)		
all patients		
■ symptomatic vertigo	1st	dietary changes and lifestyle modification
	adjunct	diuretic
	plus	vestibular suppressant, antiemetic, or corticosteroid
■ symptomatic tinnitus	adjunct	intratympanic injection
	plus	nonpharmaceutical therapy
	adjunct	antidepressant or benzodiazepine
■ sudden hearing loss	plus	corticosteroid

Ongoing (summary)		
persistent hearing loss		
	1st	amplification (hearing aid) or assistive listening device
	plus	intensive high-quality audiologic counseling
failure of medical and intratympanic therapies; hearing adequate		
	1st	endolymphatic sac surgery
	1st	vestibular nerve section
failure of medical and intratympanic therapies; hearing severely impaired		
	1st	labyrinthectomy

Treatment algorithm

Please note that formulations/routes and doses may differ between drug names and brands, drug formularies, or locations. Treatment recommendations are specific to patient groups: [see disclaimer](#)

Acute	
all patients	
1st	<p>dietary changes and lifestyle modification</p> <p>» All patients should be educated on dietary changes and lifestyle modification. Patients should be advised to restrict salt intake to 1500 to 2300 mg/day, as this is thought to prevent sodium-related water retention and redistribution into the endolymphatic system.[21] [52] Although there are no randomized controlled trials to document the benefits of low-salt diet on the treatment of meniere disease (MD), patients often report exacerbation of their symptoms or even precipitation of an attack after a salty meal.[52] [53]</p> <p>» Limiting caffeine intake, reducing alcohol consumption, ceasing smoking, and managing stress are also advisable, as these may trigger an attack. However, there is no evidence from randomized controlled trials to support or refute the restriction of salt, caffeine, or alcohol intake in patients with MD.[53] [54]</p> <p>» Such dietary changes may be the only necessary treatment required in the early stages of the disease.</p>
adjunct	<p>diuretic</p> <p>Treatment recommended for SOME patients in selected patient group</p> <p>Primary options</p> <div><p>» triamterene/hydrochlorothiazide: 37.5 mg (triamterene)/25 mg (hydrochlorothiazide) orally once daily</p><p>» acetazolamide: 250 mg orally (regular-release) twice daily</p></div> <p>» Diuretics are believed to reduce the volume of the endolymph and may be offered for maintenance therapy.[21] [55]</p> <p>» The most commonly used diuretics in the treatment of MD are thiazides with or without potassium-sparing diuretics (e.g., hydrochlorothiazide/triamterene) and acetazolamide.[21]</p>

Acute

■ symptomatic vertigo

plus

» If the patient remains symptom-free for 6 months, diuretics may be slowly tapered and restarted if required. If there is no response, the patient should be changed to the alternative diuretic. These medications should not be used in patients with a known or suspected reaction to sulfonamides.

» The evidence of the efficacy of diuretics on MD is controversial, and direct evidence of its efficacy on disease progression is lacking in the literature.^[2] However, diuretics are still considered by many physicians to be first-line treatment in all patients with MD.

vestibular suppressant, antiemetic, or corticosteroid

Treatment recommended for ALL patients in selected patient group

Primary options

» **meclizine**: 12.5 to 25 mg orally every 6 hours when required

OR

» **dimenhydrinate**: 50 mg orally every 4-6 hours when required

OR

» **promethazine**: 12.5 to 25 mg orally/rectally every 4-6 hours when required

Secondary options

» **diazepam**: 2-10 mg orally every 4-6 hours when required

OR

» **prochlorperazine maleate**: 5-10 mg orally every 6-8 hours when required

OR

» **prochlorperazine rectal**: 25 mg rectally twice daily when required

Tertiary options

» **prednisone**: 20 mg orally three times daily for 2-3 weeks, then gradually taper

» Symptoms of individual and acute vertigo spells can be treated with vestibular

Acute

suppressants and antiemetics. However, much of the effect is from the sedative action of these drugs.

» The literature lacks randomized controlled trials assessing the effects of these medications for acute attacks of MD.

» Commonly used treatments include antihistamines (e.g., meclizine, dimenhydrinate, promethazine), benzodiazepines (e.g., diazepam), and phenothiazines (e.g., prochlorperazine).[57] Diazepam should only be used in acute attacks.[21] It should be prescribed at low doses where possible, and long-term prescription avoided due to the risk of dependency. Prochlorperazine is a second-line treatment for patients with refractory nausea.

» Oral corticosteroids may be used to treat acute attacks of vertigo, especially when accompanied by acute hearing loss and tinnitus. They are widely used because of their anti-inflammatory properties, although no randomized controlled trials are available to assess their efficacy in MD.[60] The dose, indications, and duration of corticosteroids used vary in the literature. Oral corticosteroids have very well-known adverse effects but are often tolerated at such a dose and for short durations.

adjunct intratympanic injection

Treatment recommended for SOME patients in selected patient group

Primary options

» **dexamethasone sodium phosphate**: consult specialist for guidance on intratympanic dose

OR

» **methylprednisolone sodium succinate**: consult specialist for guidance on intratympanic dose

OR

» **gentamicin**: consult specialist for guidance on intratympanic dose

» Intratympanic corticosteroids: there is wide variation in the dose used, frequency of administration, and method of application in the literature. Tympanic membrane perforation and infection can occur.

Acute

■ symptomatic tinnitus

plus

» Intratympanic gentamicin: gentamicin (an aminoglycoside antibiotic) preferentially destroys the vestibular labyrinth when injected into the middle ear, resulting in chemical labyrinthectomy. In one prospective, double-blind, randomized, placebo-controlled clinical trial, intratympanic gentamicin treatment was found to reduce the score of vertigo severity and perceived aural fullness in the treatment group.[77] Evidence suggests that intratympanic gentamicin injections improve vertigo symptoms, are well tolerated, and have a low incidence of severe hearing loss.[21] However, two systematic reviews in 2023 found that the efficacy of intratympanic gentamicin and corticosteroid injections in the treatment of patients with MD is unclear due to the uncertainty of available evidence.[78] [79]

nonpharmaceutical therapy

Treatment recommended for ALL patients in selected patient group

» Patients with severe, intractable tinnitus can receive relief with a number of modalities, such as tinnitus maskers, tinnitus retraining therapy (TRT), amplifications, medication, biofeedback, and neuromonics.[67]

» Tinnitus maskers (white noise generators) are devices similar to hearing aids that fit behind the ear. They produce a quiet external sound that distracts the patient from the internal tinnitus noise. In one form of tinnitus masking, the level of the masker is increased until the patient's own tinnitus is rendered inaudible. In TRT the masker remains audible along with the patient's tinnitus, and the patient learns to adjust to the audible masking level along with his or her own tinnitus. Thus, both remain audible in a graduated situation where the patient learns to tolerate his or her own tinnitus while accepting the audible tinnitus masker.

» TRT is counseling accompanied by white noise generators. TRT is a favored treatment, but it may take up to 18 months before full benefits are achieved.[64] [65]

» Neuromonics uses a customized neural stimulus combined with specific music, delivered through a coordinated program to interact with, interrupt, and desensitize tinnitus disturbance for long-term benefit.[66] [67] [68]

» Amplifications (hearing aids) may help in masking the tinnitus.

Acute

» Biofeedback techniques attempt to decrease the anxiety that is associated with the tinnitus. This can be achieved through relaxation techniques, hypnosis, and cognitive behavioral therapy.

adjunct antidepressant or benzodiazepine

Treatment recommended for SOME patients in selected patient group

Primary options

» **amitriptyline**: 25-75 mg/day orally given in 1-3 divided doses

OR

» **alprazolam**: 0.25 to 0.5 mg orally (immediate-release) three times daily

» Medications such as antidepressants (e.g., amitriptyline) and benzodiazepines (e.g., alprazolam) may help patients with intractable tinnitus, but are associated with adverse effects.[69] They should only be used if nonpharmaceutical treatments are unsuccessful and debilitating tinnitus persists.

■ **sudden hearing loss****plus****corticosteroid**

Treatment recommended for ALL patients in selected patient group

Primary options

» **prednisone**: 20 mg orally three times daily for 2-3 weeks, then gradually taper

Secondary options

» **dexamethasone sodium phosphate**: consult specialist for guidance on intratympanic dose

OR

» **methylprednisolone sodium succinate**: consult specialist for guidance on intratympanic dose

» The dose, indications, and duration of oral corticosteroids used vary in the literature. Oral corticosteroids have very well known adverse effects but are often tolerated at such a dose and for short durations.

» Intratympanic corticosteroids are used in patients with MD where systemic corticosteroids are contraindicated, or in patients who do not respond to oral corticosteroids. There is a

Acute

wide variation in the dose used, frequency of administration, and method of application in the literature. Tympanic membrane perforation and infection can occur.

Ongoing

persistent hearing loss

1st amplification (hearing aid) or assistive listening device

» Because hearing varies dramatically in these patients, access to expert audiologic personnel for reprogramming the hearing aid(s) is essential. Use of instruments incorporating algorithms to improve word recognition in noisy listening environments is also essential.

» Amplification using fully digital hearing aids with variable digitally adjustable circuitry should be evaluated. The traditional view that amplification does not work for patients with MD is not based on experience with modern amplification.

» New forms of directional microphones, digital signal processing circuitry, and wireless technology can provide significant benefits in helping MD patients to hear better in environments with competing noise.^[70]

» Assistive listening devices are a form of amplification for those with situational difficulties in hearing, and who are not yet ready or willing to use personal hearing aids.

plus intensive high-quality audiologic counseling

Treatment recommended for ALL patients in selected patient group

» Intensive high-quality audiologic counseling is needed for patients with MD in the adjustment to, and acceptance of, amplification.

failure of medical and intratympanic therapies; hearing adequate**1st endolymphatic sac surgery**

» A nondestructive procedure that consists of decompression of the endolymphatic sac from the overlying bone and drainage of its endolymph. This maintains the vestibular neuroepithelium and its innervation.

» Decreases endolymphatic pressure and addresses both cochlear and vestibular dysfunctions.

» Its role in MD is controversial, with studies that show 90% resolution of vertigo, and others that demonstrate that it is no more effective than placebo, or that there is insufficient evidence of the beneficial effect of endolymphatic sac

Ongoing

surgery in MD.[7] [84] [85] [86] [87] [88] [89] A 2023 systematic literature search and meta-analysis revealed a paucity of studies on this surgical procedure, indicating ELS may be a beneficial treatment for patients with MD.[89] However, further studies are needed to attain a better understanding of the efficacy of ELS for treating MD.

» Endolymphatic sac surgery carries a risk of hearing loss in up to 2% of patients.[93] Other potential complications of this procedure include bleeding from the sigmoid sinus and cerebrospinal fluid leak.

1st vestibular nerve section

» In this procedure, the vestibular portion of the eighth cranial nerve (CN VIII) is selectively cut and its cochlear portion is left intact; thus, this is potentially a hearing conservation approach. This prevents the vestibular afferent stimuli from reaching the brain.

» This does not alter the pathophysiology of MD, but provides relief from vertigo, its most disturbing symptom. It should be avoided in bilateral MD, otherwise oscillopsia (perception of bouncing of the visual field with walking) and permanent imbalance may occur.

» Central compensation after vestibular nerve section is crucial for postoperative recovery of balance. Central nervous system disease such as cerebellar dysfunction, multiple sclerosis, physiologic aging, and poor medical condition are relative contraindications for vestibular nerve section.

» Vertigo control rates are up to 90% with vestibular nerve section.[94] [95] Persistent or recurrent vertigo after vestibular nerve section can be treated by intratympanic gentamicin.

» Potential complications are uncommon and include hearing loss, facial nerve paralysis, cerebrospinal fluid leak, and headache.[94]

failure of medical and intratympanic therapies; hearing severely impaired

1st labyrinthectomy

» Involves surgical removal of the inner ear's neuroepithelium in an attempt to eliminate vertigo.

» Hearing loss is inevitable with this procedure and it should only be used in patients with no

Ongoing

serviceable hearing. Avoided in patients with bilateral disease, as bilateral loss of vestibular input to the brain may result in oscillopsia (perception of bouncing of the visual field with walking) and permanent imbalance.

» Central compensation after labyrinthectomy is important for balance recovery, and vestibular rehabilitation therapy after surgery may help speed the recovery. Central nervous system disease, advanced age, and a variety of significant medical conditions can prevent central compensation after surgery and these patients are, therefore, not good candidates for labyrinthectomy.

» Vertigo control rates up to 97% after have been reported.[\[96\]](#)

» Complications from labyrinthectomy include facial nerve injury (2%) and cerebrospinal fluid leak in 3%.[\[97\]](#)

Patient discussions

All patients should be educated on dietary changes and lifestyle modification. Patients with meniere disease (MD) should be advised to restrict salt intake to 1500 to 2300 mg/day. Limiting caffeine intake, reducing alcohol consumption, ceasing smoking, and managing stress are also advisable, as these may trigger an attack. However, there is no evidence from randomized controlled trials to support or refute the restriction of salt, caffeine, or alcohol intake in patients with MD.[\[53\]](#)

Monitoring

Monitoring

Meniere disease is considered a chronic disease whose activity might wax and wane over time. Patients are usually followed up for a long period of time with an otologist and an audiologist. Regular hearing tests are obtained to monitor hearing acuity and to provide appropriate amplification as needed. Patients' symptoms are monitored and treated accordingly. Dietary restrictions should be routinely reinforced, and medical or surgical therapy should be provided when needed.

Complications

Complications	Timeframe	Likelihood
falls	variable	medium
Patients who complain of imbalance and unsteadiness are at higher risk of falls. Vestibular dysfunction is an important cause of falls, where around 80% of patients who had unexplained falls were found to have symptoms of vestibular system involvement and 41% to have vertigo.[99] Patients with drop attacks are also predisposed to fall during attacks.[9]		
profound hearing loss	variable	low
Hearing loss is one of the manifestations of the disease. The incidence of bilateral, severe to profound hearing loss is estimated at 1% to 6%.[98]		

Prognosis

Most patients start with hearing loss and tinnitus. Patients may or may not then develop the complete clinical profile of meniere disease (MD).[3]

Symptoms tend to get worse over time regardless of medical intervention. MD goes into periods of remission that are variable in duration and frequency.[3] Disproportionately greater hearing loss in low frequencies during early stages is often accompanied by disproportionately greater loss in speech comprehension than would be anticipated by degree of sensitivity. The progression of hearing loss over time is unpredictable for the individual patient.

Diagnostic guidelines

International

Clinical practice guideline: Ménière's disease (<https://www.entnet.org/content/clinical-practice-guidelines>) [21]

Published by: American Academy of Otolaryngology - Head and Neck Surgery Foundation

Last published: 2020

Clinical practice guideline: sudden hearing loss (update) (<https://www.entnet.org/content/clinical-practice-guidelines>) [46]

Published by: American Academy of Otolaryngology - Head and Neck Surgery Foundation

Last published: 2019

ACR appropriateness criteria: hearing loss and/or vertigo (<https://www.acr.org/Clinical-Resources/ACR-Appropriateness-Criteria>) [47]

Published by: American College of Radiology

Last published: 2018

Diagnostic criteria for Ménière's disease (<http://www.jvr-web.org/ICVD.html>) [45]

Published by: Bárány Society, Japan Society for Equilibrium Research, European Academy of Otology and Neurotology, American Academy of Otolaryngology-Head and Neck Surgery, Korean Balance Society

Last published: 2015

Treatment guidelines

International

Clinical practice guideline: Ménière's disease (<https://www.entnet.org/content/clinical-practice-guidelines>) [21]

Published by: American Academy of Otolaryngology - Head and Neck Surgery Foundation

Last published: 2020

Key articles

- Goebel JA. 2015 Equilibrium Committee amendment to the 1995 AAO-HNS guidelines for the definition of Ménière's disease. *Otolaryngol Head Neck Surg.* 2016 Mar;154(3):403-4. [Abstract \(http://www.ncbi.nlm.nih.gov/pubmed/26884364?tool=bestpractice.bmj.com\)](http://www.ncbi.nlm.nih.gov/pubmed/26884364?tool=bestpractice.bmj.com)
- Basura GJ, Adams ME, Monfared A, et al. Clinical practice guideline: Ménière's disease. *Otolaryngol Head Neck Surg.* 2020 Apr;162(suppl 2):S1-55. [Full text \(https://aao-hnsfjournals.onlinelibrary.wiley.com/doi/10.1177/0194599820909438\)](https://aao-hnsfjournals.onlinelibrary.wiley.com/doi/10.1177/0194599820909438) [Abstract \(http://www.ncbi.nlm.nih.gov/pubmed/32267799?tool=bestpractice.bmj.com\)](http://www.ncbi.nlm.nih.gov/pubmed/32267799?tool=bestpractice.bmj.com)
- Lopez-Escamez JA, Carey J, Chung WH, et al; Classification Committee of the Barany Society; Japan Society for Equilibrium Research; European Academy of Otolology and Neurotology (EAONO); Equilibrium Committee of the American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS); Korean Balance Society. Diagnostic criteria for Ménière's disease. *J Vestib Res.* 2015;25(1):1-7. [Full text \(https://content.iospress.com/download/journal-of-vestibular-research/ves00549?id=journal-of-vestibular-research%2Fves00549\)](https://content.iospress.com/download/journal-of-vestibular-research/ves00549?id=journal-of-vestibular-research%2Fves00549) [Abstract \(http://www.ncbi.nlm.nih.gov/pubmed/25882471?tool=bestpractice.bmj.com\)](http://www.ncbi.nlm.nih.gov/pubmed/25882471?tool=bestpractice.bmj.com)
- American College of Radiology. ACR appropriateness criteria: hearing loss and/or vertigo. 2018 [internet publication]. [Full text \(https://acsearch.acr.org/docs/69488/Narrative\)](https://acsearch.acr.org/docs/69488/Narrative)

References

1. Goebel JA. 2015 Equilibrium Committee amendment to the 1995 AAO-HNS guidelines for the definition of Ménière's disease. *Otolaryngol Head Neck Surg.* 2016 Mar;154(3):403-4. [Abstract \(http://www.ncbi.nlm.nih.gov/pubmed/26884364?tool=bestpractice.bmj.com\)](http://www.ncbi.nlm.nih.gov/pubmed/26884364?tool=bestpractice.bmj.com)
2. Thirlwall AS, Kundu S. Diuretics for Ménière's disease or syndrome. *Cochrane Database Syst Rev.* 2006 Jul 19;(3):CD003599. [Full text \(https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003599.pub2/full\)](https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003599.pub2/full) [Abstract \(http://www.ncbi.nlm.nih.gov/pubmed/16856015?tool=bestpractice.bmj.com\)](http://www.ncbi.nlm.nih.gov/pubmed/16856015?tool=bestpractice.bmj.com)
3. da Costa SS, de Sousa LC, Piza MR. Meniere's disease: overview, epidemiology, and natural history. *Otolaryngol Clin North Am.* 2002 Jun;35(3):455-95. [Abstract \(http://www.ncbi.nlm.nih.gov/pubmed/12486835?tool=bestpractice.bmj.com\)](http://www.ncbi.nlm.nih.gov/pubmed/12486835?tool=bestpractice.bmj.com)
4. Committee on Hearing and Equilibrium guidelines for the diagnosis and evaluation of therapy in Ménière's disease. American Academy of Otolaryngology-Head and Neck Foundation, Inc. *Otolaryngol Head Neck Surg.* 1995 Sep;113(3):181-5.
5. Wladislavosky-Waserman P, Facer GW, Mokri B, et al. Meniere's disease: a 30-year epidemiologic and clinical study in Rochester, MN, 1951-1980. *Laryngoscope.* 1984 Aug;94(8):1098-102. [Abstract \(http://www.ncbi.nlm.nih.gov/pubmed/6611471?tool=bestpractice.bmj.com\)](http://www.ncbi.nlm.nih.gov/pubmed/6611471?tool=bestpractice.bmj.com)

6. Kim MH, Cheon C. Epidemiology and seasonal variation of Ménière's disease: data from a population-based study. *Audiol Neurotol*. 2020;25(4):224-30. [Abstract \(http://www.ncbi.nlm.nih.gov/pubmed/32289780?tool=bestpractice.bmj.com\)](http://www.ncbi.nlm.nih.gov/pubmed/32289780?tool=bestpractice.bmj.com)
7. Paparella MM. Pathogenesis and pathophysiology of Meniere's disease. *Acta Otolaryngol Suppl*. 1991;111(suppl 485):26-35. [Abstract \(http://www.ncbi.nlm.nih.gov/pubmed/1843169?tool=bestpractice.bmj.com\)](http://www.ncbi.nlm.nih.gov/pubmed/1843169?tool=bestpractice.bmj.com)
8. Zhang S, Guo Z, Tian E, et al. Meniere disease subtyping: the direction of diagnosis and treatment in the future. *Expert Rev Neurother*. 2022 Feb;22(2):115-27. [Full text \(https://www.tandfonline.com/doi/full/10.1080/14737175.2022.2030221\)](https://www.tandfonline.com/doi/full/10.1080/14737175.2022.2030221) [Abstract \(http://www.ncbi.nlm.nih.gov/pubmed/35057670?tool=bestpractice.bmj.com\)](http://www.ncbi.nlm.nih.gov/pubmed/35057670?tool=bestpractice.bmj.com)
9. Huppert D, Strupp M, Brandt T. Long-term course of Menière's disease revisited. *Acta Otolaryngol*. 2010 Jun;130(6):644-51. [Abstract \(http://www.ncbi.nlm.nih.gov/pubmed/20001444?tool=bestpractice.bmj.com\)](http://www.ncbi.nlm.nih.gov/pubmed/20001444?tool=bestpractice.bmj.com)
10. Morita Y, Takahashi K, Ohshima S, et al. Is vestibular Meniere's disease associated with endolymphatic hydrops? *Front Surg*. 2020 Dec 18;7:601692. [Full text \(https://www.frontiersin.org/articles/10.3389/fsurg.2020.601692/full\)](https://www.frontiersin.org/articles/10.3389/fsurg.2020.601692/full) [Abstract \(http://www.ncbi.nlm.nih.gov/pubmed/33392247?tool=bestpractice.bmj.com\)](http://www.ncbi.nlm.nih.gov/pubmed/33392247?tool=bestpractice.bmj.com)
11. Lee CS, Paparella MM, Margolis RH, et al. Audiological profiles and Menière's disease. *Ear Nose Throat J*. 1995 Aug;74(8):527-32. [Abstract \(http://www.ncbi.nlm.nih.gov/pubmed/7555870?tool=bestpractice.bmj.com\)](http://www.ncbi.nlm.nih.gov/pubmed/7555870?tool=bestpractice.bmj.com)
12. Conlon BJ, Gibson WP. Meniere's disease: the incidence of hydrops in the contralateral asymptomatic ear. *Laryngoscope*. 1999 Nov;109(11):1800-2. [Abstract \(http://www.ncbi.nlm.nih.gov/pubmed/10569410?tool=bestpractice.bmj.com\)](http://www.ncbi.nlm.nih.gov/pubmed/10569410?tool=bestpractice.bmj.com)
13. Pulec L, House WF. Meniere's disease study: three-year progress report. *Int J Equilib Res*. 1973 Jun;3(1):156-65. [Abstract \(http://www.ncbi.nlm.nih.gov/pubmed/4807558?tool=bestpractice.bmj.com\)](http://www.ncbi.nlm.nih.gov/pubmed/4807558?tool=bestpractice.bmj.com)
14. Pulec JL. Meniere's disease. Etiology, natural history, and results of treatment. *Otolaryngol Clin North Am*. 1973 Feb;6(1):25-39. [Abstract \(http://www.ncbi.nlm.nih.gov/pubmed/4220281?tool=bestpractice.bmj.com\)](http://www.ncbi.nlm.nih.gov/pubmed/4220281?tool=bestpractice.bmj.com)
15. Paparella MM, Djalilian HR. Etiology, pathophysiology of symptoms, and pathogenesis of Meniere's disease. *Otolaryngol Clin North Am*. 2002 Jun;35(3):529-45, vi. [Abstract \(http://www.ncbi.nlm.nih.gov/pubmed/12486838?tool=bestpractice.bmj.com\)](http://www.ncbi.nlm.nih.gov/pubmed/12486838?tool=bestpractice.bmj.com)
16. Merchant SN, Adams JC, Nadol JB Jr. Pathophysiology of Meniere's syndrome: are symptoms caused by endolymphatic hydrops? *Otol Neurotol*. 2005 Jan;26(1):74-81. [Abstract \(http://www.ncbi.nlm.nih.gov/pubmed/15699723?tool=bestpractice.bmj.com\)](http://www.ncbi.nlm.nih.gov/pubmed/15699723?tool=bestpractice.bmj.com)
17. Gürkov R, Pyykö I, Zou J, et al. What is Menière's disease? A contemporary re-evaluation of endolymphatic hydrops. *J Neurol*. 2016 Apr 15;263(suppl 1):S71-81. [Full text \(https://](https://)

- link.springer.com/article/10.1007%2Fs00415-015-7930-1) Abstract (<http://www.ncbi.nlm.nih.gov/pubmed/27083887?tool=bestpractice.bmj.com>)
18. Paparella MM, Fina M. Endolymphatic sac enhancement: reversal of pathogenesis. *Otolaryngol Clin North Am*. 2002 Jun;35(3):621-37. Abstract (<http://www.ncbi.nlm.nih.gov/pubmed/12486844?tool=bestpractice.bmj.com>)
 19. Selmani Z, Marttila T, Pyykko I. Incidence of virus infection as a cause of Meniere's disease or endolymphatic hydrops assessed by electrocochleography. *Eur Arch Otorhinolaryngol*. 2005 Apr;262(4):331-4. Abstract (<http://www.ncbi.nlm.nih.gov/pubmed/15235799?tool=bestpractice.bmj.com>)
 20. de Sousa LC, Piza MR, da Costa SS. Diagnosis of Meniere's disease: routine and extended tests. *Otolaryngol Clin North Am*. 2002 Jun;35(3):547-64. Abstract (<http://www.ncbi.nlm.nih.gov/pubmed/12486839?tool=bestpractice.bmj.com>)
 21. Basura GJ, Adams ME, Monfared A, et al. Clinical practice guideline: Ménière's disease. *Otolaryngol Head Neck Surg*. 2020 Apr;162(suppl 2):S1-55. Full text (<https://aao-hnsfjournals.onlinelibrary.wiley.com/doi/10.1177/0194599820909438>) Abstract (<http://www.ncbi.nlm.nih.gov/pubmed/32267799?tool=bestpractice.bmj.com>)
 22. Grant IL, Welling DB. The treatment of hearing loss in Meniere's disease. *Otolaryngol Clin North Am*. 1997 Dec;30(6):1123-44. Abstract (<http://www.ncbi.nlm.nih.gov/pubmed/9386248?tool=bestpractice.bmj.com>)
 23. Ballester M, Liard P, Vibert D, et al. Meniere's disease in the elderly. *Otol Neurotol*. 2002 Jan;23(1):73-8. Abstract (<http://www.ncbi.nlm.nih.gov/pubmed/11773851?tool=bestpractice.bmj.com>)
 24. Kentala E, Havia M, Pyykko I. Short-lasting drop attacks in Meniere's disease. *Otolaryngol Head Neck Surg*. 2001 May;124(5):526-30. Abstract (<http://www.ncbi.nlm.nih.gov/pubmed/11337657?tool=bestpractice.bmj.com>)
 25. Gibson WP, Moffat DA, Ramsden RT. Clinical electrocochleography in the diagnosis and management of Ménière's disorder. *Audiology*. 1977 Sep-Oct;16(5):389-401. Abstract (<http://www.ncbi.nlm.nih.gov/pubmed/901293?tool=bestpractice.bmj.com>)
 26. Ferraro JA, Durrant JD. Electrocochleography in the evaluation of patients with Ménière's disease/endolymphatic hydrops. *J Am Acad Audiol*. 2006 Jan;17(1):45-68. Abstract (<http://www.ncbi.nlm.nih.gov/pubmed/16640060?tool=bestpractice.bmj.com>)
 27. Conlon BJ, Gibson WP. Electrocochleography in the diagnosis of Meniere's disease. *Acta Otolaryngol*. 2000 Jun;120(4):480-3. Abstract (<http://www.ncbi.nlm.nih.gov/pubmed/10958398?tool=bestpractice.bmj.com>)
 28. Al-momani MO, Ferraro JA, Gajewski BJ, et al. Improved sensitivity of electrocochleography in the diagnosis of Meniere's disease. *Int J Audiol*. 2009 Nov;48(11):811-9. Abstract (<http://www.ncbi.nlm.nih.gov/pubmed/19951149?tool=bestpractice.bmj.com>)

29. Ferraro JA. Electrocochleography: a review of recording approaches, clinical applications, and new findings in adults and children. *J Am Acad Audiol*. 2010 Mar;21(3):145-52. [Abstract \(http://www.ncbi.nlm.nih.gov/pubmed/20211118?tool=bestpractice.bmj.com\)](http://www.ncbi.nlm.nih.gov/pubmed/20211118?tool=bestpractice.bmj.com)
30. Ferraro J. Electrocochleography. In: Ross JR, Valente M, Hosford-Dunn H, eds. *Audiologic diagnosis*. 2nd ed. New York, NY: Thieme; 2000:425-50.
31. Xiao H, Guo X, Cai H, et al. Magnetic resonance imaging of endolymphatic hydrops in Ménière's disease: a comparison of the diagnostic value of multiple scoring methods. *Front Neurol*. 2022 Sep 26;13:967323. [Full text \(https://www.frontiersin.org/articles/10.3389/fneur.2022.967323/full\)](https://www.frontiersin.org/articles/10.3389/fneur.2022.967323/full) [Abstract \(http://www.ncbi.nlm.nih.gov/pubmed/36247770?tool=bestpractice.bmj.com\)](http://www.ncbi.nlm.nih.gov/pubmed/36247770?tool=bestpractice.bmj.com)
32. Gürkov R, Flatz W, Louza J, et al. In vivo visualization of endolymphatic hydrops in patients with Meniere's disease: correlation with audiovestibular function. *Eur Arch Otorhinolaryngol*. 2011 Dec;268(12):1743-8. [Abstract \(http://www.ncbi.nlm.nih.gov/pubmed/21431434?tool=bestpractice.bmj.com\)](http://www.ncbi.nlm.nih.gov/pubmed/21431434?tool=bestpractice.bmj.com)
33. Sano R, Teranishi M, Yamazaki M, et al. Contrast enhancement of the inner ear in magnetic resonance images taken at 10 minutes or 4 hours after intravenous gadolinium injection. *Acta Otolaryngol*. 2012 Mar;132(3):241-6. [Abstract \(http://www.ncbi.nlm.nih.gov/pubmed/22201230?tool=bestpractice.bmj.com\)](http://www.ncbi.nlm.nih.gov/pubmed/22201230?tool=bestpractice.bmj.com)
34. Liu Y, Pyykkö I, Naganawa S, et al. Consensus on MR imaging of endolymphatic hydrops in patients with suspected hydropic ear disease (Meniere). *Front Surg*. 2022 Apr 28;9:874971. [Full text \(https://www.frontiersin.org/articles/10.3389/fsurg.2022.874971/full\)](https://www.frontiersin.org/articles/10.3389/fsurg.2022.874971/full) [Abstract \(http://www.ncbi.nlm.nih.gov/pubmed/35574547?tool=bestpractice.bmj.com\)](http://www.ncbi.nlm.nih.gov/pubmed/35574547?tool=bestpractice.bmj.com)
35. Agrup C, Luxon LM. Immune-mediated inner-ear disorders in neuro-otology. *Curr Opin Neurol*. 2006 Feb;19(1):26-32. [Abstract \(http://www.ncbi.nlm.nih.gov/pubmed/16415674?tool=bestpractice.bmj.com\)](http://www.ncbi.nlm.nih.gov/pubmed/16415674?tool=bestpractice.bmj.com)
36. Jerger J, Jerger S. Diagnostic significance of PB word functions. *Arch Otolaryngol*. 1971 Jun;93(6):573-80. [Abstract \(http://www.ncbi.nlm.nih.gov/pubmed/5314647?tool=bestpractice.bmj.com\)](http://www.ncbi.nlm.nih.gov/pubmed/5314647?tool=bestpractice.bmj.com)
37. Fetterman BL. Distortion-product otoacoustic emissions and cochlear microphonics: relationships in patients with and without endolymphatic hydrops. *Laryngoscope*. 2001 Jun;111(6):946-54. [Abstract \(http://www.ncbi.nlm.nih.gov/pubmed/11404602?tool=bestpractice.bmj.com\)](http://www.ncbi.nlm.nih.gov/pubmed/11404602?tool=bestpractice.bmj.com)
38. Young YH, Huang TW, Cheng PW. Assessing the stage of Meniere's disease using vestibular evoked myogenic potentials. *Arch Otolaryngol Head Neck Surg*. 2003 Aug;129(8):815-8. [Abstract \(http://www.ncbi.nlm.nih.gov/pubmed/12925337?tool=bestpractice.bmj.com\)](http://www.ncbi.nlm.nih.gov/pubmed/12925337?tool=bestpractice.bmj.com)
39. Kentala E, Pyykkö I. Vestibular schwannoma mimicking Ménière's disease. *Acta Otolaryngol Suppl*. 2000;120(suppl 543):17-9. [Abstract \(http://www.ncbi.nlm.nih.gov/pubmed/10908964?tool=bestpractice.bmj.com\)](http://www.ncbi.nlm.nih.gov/pubmed/10908964?tool=bestpractice.bmj.com)
40. Shepard NT. Differentiation of Ménière's disease and migraine-associated dizziness: a review. *J Am Acad Audiol*. 2006 Jan;17(1):69-80. [Abstract \(http://www.ncbi.nlm.nih.gov/pubmed/16640061?tool=bestpractice.bmj.com\)](http://www.ncbi.nlm.nih.gov/pubmed/16640061?tool=bestpractice.bmj.com)

41. Roland PS, Marple BF, Meyerhoff WL, eds. Hearing loss. New York, NY: Thieme Medical Publishers, Inc.; 1997.
42. Karlberg M, Hall K, Quickert N, et al. What inner ear diseases cause benign paroxysmal positional vertigo? *Acta Otolaryngol.* 2000 Mar;120(3):380-5. [Abstract \(http://www.ncbi.nlm.nih.gov/pubmed/10894413?tool=bestpractice.bmj.com\)](http://www.ncbi.nlm.nih.gov/pubmed/10894413?tool=bestpractice.bmj.com)
43. Bhattacharyya N, Gubbels SP, Schwartz SR, et al. Clinical practice guideline: benign paroxysmal positional vertigo (update). *Otolaryngol Head Neck Surg.* 2017 Mar;156(3 suppl):S1-47. [Full text \(https://journals.sagepub.com/doi/full/10.1177/0194599816689667\)](https://journals.sagepub.com/doi/full/10.1177/0194599816689667) [Abstract \(http://www.ncbi.nlm.nih.gov/pubmed/28248609?tool=bestpractice.bmj.com\)](http://www.ncbi.nlm.nih.gov/pubmed/28248609?tool=bestpractice.bmj.com)
44. Baloh RW. The dizzy patient. *Postgrad Med.* 1999 Feb;105(2):161-4, 167-72. [Abstract \(http://www.ncbi.nlm.nih.gov/pubmed/10026710?tool=bestpractice.bmj.com\)](http://www.ncbi.nlm.nih.gov/pubmed/10026710?tool=bestpractice.bmj.com)
45. Lopez-Escamez JA, Carey J, Chung WH, et al; Classification Committee of the Barany Society; Japan Society for Equilibrium Research; European Academy of Otolology and Neurotology (EAONO); Equilibrium Committee of the American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS); Korean Balance Society. Diagnostic criteria for Menière's disease. *J Vestib Res.* 2015;25(1):1-7. [Full text \(https://content.iospress.com/download/journal-of-vestibular-research/ves00549?id=journal-of-vestibular-research%2Fves00549\)](https://content.iospress.com/download/journal-of-vestibular-research/ves00549?id=journal-of-vestibular-research%2Fves00549) [Abstract \(http://www.ncbi.nlm.nih.gov/pubmed/25882471?tool=bestpractice.bmj.com\)](http://www.ncbi.nlm.nih.gov/pubmed/25882471?tool=bestpractice.bmj.com)
46. Chandrasekhar SS, Tsai Do BS, Schwartz SR, et al. Clinical practice guideline: sudden hearing loss (update). *Otolaryngol Head Neck Surg.* 2019 Aug;161(suppl 1):S1-45. [Full text \(https://journals.sagepub.com/doi/10.1177/0194599819859885?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed\)](https://journals.sagepub.com/doi/10.1177/0194599819859885?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed) [Abstract \(http://www.ncbi.nlm.nih.gov/pubmed/31369359?tool=bestpractice.bmj.com\)](http://www.ncbi.nlm.nih.gov/pubmed/31369359?tool=bestpractice.bmj.com)
47. American College of Radiology. ACR appropriateness criteria: hearing loss and/or vertigo. 2018 [internet publication]. [Full text \(https://acsearch.acr.org/docs/69488/Narrative\)](https://acsearch.acr.org/docs/69488/Narrative)
48. Kinney SE, Sandridge SA, Newman CW. Long-term effects of Ménière's disease on hearing and quality of life. *Am J Otol.* 1997 Jan;18(1):67-73. [Abstract \(http://www.ncbi.nlm.nih.gov/pubmed/8989954?tool=bestpractice.bmj.com\)](http://www.ncbi.nlm.nih.gov/pubmed/8989954?tool=bestpractice.bmj.com)
49. Hamill TA. Evaluating treatments for Ménière's disease: controversies surrounding placebo control. *J Am Acad Audiol.* 2006 Jan;17(1):27-37. [Abstract \(http://www.ncbi.nlm.nih.gov/pubmed/16640058?tool=bestpractice.bmj.com\)](http://www.ncbi.nlm.nih.gov/pubmed/16640058?tool=bestpractice.bmj.com)
50. Gacek RR, Gacek MR. Ménière's disease as a manifestation of vestibular ganglionitis. *Am J Otolaryngol.* 2001 Jul-Aug;22(4):241-50. [Abstract \(http://www.ncbi.nlm.nih.gov/pubmed/11464320?tool=bestpractice.bmj.com\)](http://www.ncbi.nlm.nih.gov/pubmed/11464320?tool=bestpractice.bmj.com)
51. Rickenstein MJ, Harrison RV. Cochlear pathophysiology in Meniere's disease: a critical appraisal. In: Harris JP, ed. Ménière's disease. The Hague, Netherlands: Kugler Publications; 1999:195-202.

52. Colletti V. Medical treatment in Meniere's disease: avoiding vestibular neurectomy and facilitating postoperative compensation. *Acta Otolaryngol Suppl.* 2000;120(suppl 544):27-33. [Abstract \(http://www.ncbi.nlm.nih.gov/pubmed/10904798?tool=bestpractice.bmj.com\)](http://www.ncbi.nlm.nih.gov/pubmed/10904798?tool=bestpractice.bmj.com)
53. Hussain K, Murdin L, Schilder AG. Restriction of salt, caffeine and alcohol intake for the treatment of Ménière's disease or syndrome. *Cochrane Database Syst Rev.* 2018 Dec 31;(12):CD012173. [Full text \(https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012173.pub2/full\)](https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012173.pub2/full) [Abstract \(http://www.ncbi.nlm.nih.gov/pubmed/30596397?tool=bestpractice.bmj.com\)](http://www.ncbi.nlm.nih.gov/pubmed/30596397?tool=bestpractice.bmj.com)
54. Webster KE, George B, Lee A, et al. Lifestyle and dietary interventions for Ménière's disease. *Cochrane Database Syst Rev.* 2023 Feb 27;2(2):CD015244. [Full text \(https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015244.pub2/full\)](https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015244.pub2/full) [Abstract \(http://www.ncbi.nlm.nih.gov/pubmed/36848645?tool=bestpractice.bmj.com\)](http://www.ncbi.nlm.nih.gov/pubmed/36848645?tool=bestpractice.bmj.com)
55. Webster KE, Galbraith K, Harrington-Benton NA, et al. Systemic pharmacological interventions for Ménière's disease. *Cochrane Database Syst Rev.* 2023 Feb 23;2(2):CD015171. [Full text \(https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015171.pub2/full\)](https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015171.pub2/full) [Abstract \(http://www.ncbi.nlm.nih.gov/pubmed/36827524?tool=bestpractice.bmj.com\)](http://www.ncbi.nlm.nih.gov/pubmed/36827524?tool=bestpractice.bmj.com)
56. Nishiyama S, Okada T, Kobayashi T, et al. Na-K-ATPase activity in the guinea pig stria vascularis in experimentally-induced endolymphatic hydrops. *Histol Histopathol.* 1994 Apr;9(2):205-9. [Abstract \(http://www.ncbi.nlm.nih.gov/pubmed/8075476?tool=bestpractice.bmj.com\)](http://www.ncbi.nlm.nih.gov/pubmed/8075476?tool=bestpractice.bmj.com)
57. Soto E, Vega R. Neuropharmacology of vestibular system disorders. *Curr Neuropharmacol.* 2010 Mar;8(1):26-40. [Full text \(https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2866460\)](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2866460) [Abstract \(http://www.ncbi.nlm.nih.gov/pubmed/20808544?tool=bestpractice.bmj.com\)](http://www.ncbi.nlm.nih.gov/pubmed/20808544?tool=bestpractice.bmj.com)
58. James AL, Burton MJ. Betahistine for Ménière's disease or syndrome. *Cochrane Database Syst Rev.* 2001 Jan 22;(1):CD001873. [Full text \(https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001873/full\)](https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001873/full) [Abstract \(http://www.ncbi.nlm.nih.gov/pubmed/11279734?tool=bestpractice.bmj.com\)](http://www.ncbi.nlm.nih.gov/pubmed/11279734?tool=bestpractice.bmj.com)
59. Adrion C, Fischer CS, Wagner J, et al. Efficacy and safety of betahistine treatment in patients with Meniere's disease: primary results of a long term, multicentre, double blind, randomised, placebo controlled, dose defining trial (BEMED trial). *BMJ.* 2016 Jan 21;352:h6816. [Full text \(https://www.bmj.com/content/352/bmj.h6816.long\)](https://www.bmj.com/content/352/bmj.h6816.long) [Abstract \(http://www.ncbi.nlm.nih.gov/pubmed/26797774?tool=bestpractice.bmj.com\)](http://www.ncbi.nlm.nih.gov/pubmed/26797774?tool=bestpractice.bmj.com)
60. Silverstein H, Isaacson JE, Olds MJ, et al. Dexamethasone inner ear perfusion for the treatment of Meniere's disease: a prospective, randomized, double-blind, crossover trial. *Am J Otol.* 1998 Mar;19(2):196-201. [Abstract \(http://www.ncbi.nlm.nih.gov/pubmed/9520056?tool=bestpractice.bmj.com\)](http://www.ncbi.nlm.nih.gov/pubmed/9520056?tool=bestpractice.bmj.com)
61. Newman CW, Weinstein BE, Jacobson GP, et al. The Hearing Handicap Inventory for Adults: psychometric adequacy and audiometric correlates. *Ear Hear.* 1990 Dec;11(6):430-3. [Abstract \(http://www.ncbi.nlm.nih.gov/pubmed/2073976?tool=bestpractice.bmj.com\)](http://www.ncbi.nlm.nih.gov/pubmed/2073976?tool=bestpractice.bmj.com)

62. Newman CW, Jacobson GP, Spitzer JB. Development of the Tinnitus Handicap Inventory. Arch Otolaryngol Head Neck Surg. 1996 Feb;122(2):143-8. [Abstract \(http://www.ncbi.nlm.nih.gov/pubmed/8630207?tool=bestpractice.bmj.com\)](http://www.ncbi.nlm.nih.gov/pubmed/8630207?tool=bestpractice.bmj.com)
63. Newman CW, Sandridge SA, Jacobson GP. Psychometric adequacy of the Tinnitus Handicap Inventory (THI) for evaluating treatment outcome. J Am Acad Audiol. 1998 Apr;9(2):153-60. [Abstract \(http://www.ncbi.nlm.nih.gov/pubmed/9564679?tool=bestpractice.bmj.com\)](http://www.ncbi.nlm.nih.gov/pubmed/9564679?tool=bestpractice.bmj.com)
64. Jastreboff PJ, Hazell JW. A neurophysiological approach to tinnitus: clinical implications. Br J Audiol. 1993 Feb;27(1):7-17. [Abstract \(http://www.ncbi.nlm.nih.gov/pubmed/8339063?tool=bestpractice.bmj.com\)](http://www.ncbi.nlm.nih.gov/pubmed/8339063?tool=bestpractice.bmj.com)
65. Jastreboff PJ, Hazell JW. Treatment of tinnitus based on a neurophysiological model. In: Vernon J, ed. Tinnitus: treatment and relief. Boston, MA: Allyn & Bacon; 1998:201-16.
66. Davis PB, Paki B, Hanley PJ. Neuromonics Tinnitus Treatment: third clinical trial. Ear Hear. 2007 Apr;28(2):242-59. [Abstract \(http://www.ncbi.nlm.nih.gov/pubmed/17496674?tool=bestpractice.bmj.com\)](http://www.ncbi.nlm.nih.gov/pubmed/17496674?tool=bestpractice.bmj.com)
67. Hanley PJ, Davis PB, Paki B, et al. Treatment of tinnitus with a customized, dynamic acoustic neural stimulus: clinical outcomes in general private practice. Ann Otol Rhinol Laryngol. 2008 Nov;117(11):791-9. [Abstract \(http://www.ncbi.nlm.nih.gov/pubmed/19102123?tool=bestpractice.bmj.com\)](http://www.ncbi.nlm.nih.gov/pubmed/19102123?tool=bestpractice.bmj.com)
68. Davis PB, Wilde RA, Steed LG, et al. Treatment of tinnitus with a customized acoustic neural stimulus: a controlled clinical study. Ear Nose Throat J. 2008 Jun;87(6):330-9. [Abstract \(http://www.ncbi.nlm.nih.gov/pubmed/18561116?tool=bestpractice.bmj.com\)](http://www.ncbi.nlm.nih.gov/pubmed/18561116?tool=bestpractice.bmj.com)
69. Johnson RM, Brummett R, Schleuning A. Use of alprazolam for relief of tinnitus. A double-blind study. Arch Otolaryngol Head Neck Surg. 1993 Aug;119(8):842-5. [Abstract \(http://www.ncbi.nlm.nih.gov/pubmed/8343245?tool=bestpractice.bmj.com\)](http://www.ncbi.nlm.nih.gov/pubmed/8343245?tool=bestpractice.bmj.com)
70. Valente M, Mispagel K, Valente LM, et al. Problems and solutions for fitting amplification to patients with Meniere's disease. J Am Acad Audiol. 2006 Jan;17(1):6-15. [Abstract \(http://www.ncbi.nlm.nih.gov/pubmed/16640056?tool=bestpractice.bmj.com\)](http://www.ncbi.nlm.nih.gov/pubmed/16640056?tool=bestpractice.bmj.com)
71. Patel M, Agarwal K, Arshad Q, et al. Intratympanic methylprednisolone versus gentamicin in patients with unilateral Ménière's disease: a randomised, double-blind, comparative effectiveness trial. Lancet. 2016 Dec 3;388(10061):2753-62. [Full text \(https://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(16\)31461-1/fulltext\)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(16)31461-1/fulltext) [Abstract \(http://www.ncbi.nlm.nih.gov/pubmed/27865535?tool=bestpractice.bmj.com\)](http://www.ncbi.nlm.nih.gov/pubmed/27865535?tool=bestpractice.bmj.com)
72. Shea JJ, Ge X. Dexamethasone perfusion of the labyrinth plus intravenous dexamethasone for Ménière's disease. Otolaryngol Clin North Am. 1996 Apr;29(2):353-8. [Abstract \(http://www.ncbi.nlm.nih.gov/pubmed/8860933?tool=bestpractice.bmj.com\)](http://www.ncbi.nlm.nih.gov/pubmed/8860933?tool=bestpractice.bmj.com)

73. Shea JJ. The role of dexamethasone or streptomycin perfusion in the treatment of Meniere's disease. *Otolaryngol Clin North Am.* 1997 Dec;30(6):1051-9. [Abstract \(http://www.ncbi.nlm.nih.gov/pubmed/9386241?tool=bestpractice.bmj.com\)](http://www.ncbi.nlm.nih.gov/pubmed/9386241?tool=bestpractice.bmj.com)
74. Barrs DM, Keyser JS, Stallworth C, et al. Intratympanic steroid injections for intractable Ménière's disease. *Laryngoscope.* 2001 Dec;111(12):2100-4. [Abstract \(http://www.ncbi.nlm.nih.gov/pubmed/11802004?tool=bestpractice.bmj.com\)](http://www.ncbi.nlm.nih.gov/pubmed/11802004?tool=bestpractice.bmj.com)
75. Chia SH, Gamst AC, Anderson JP, et al. Intratympanic gentamicin therapy for Meniere's disease: a meta-analysis. *Otol Neurotol.* 2004 Jul;25(4):544-52. [Abstract \(http://www.ncbi.nlm.nih.gov/pubmed/15241234?tool=bestpractice.bmj.com\)](http://www.ncbi.nlm.nih.gov/pubmed/15241234?tool=bestpractice.bmj.com)
76. Cohen-Kerem R, Kisilevsky V, Einarson TR, et al. Intratympanic gentamicin for Ménière's disease: a meta-analysis. *Laryngoscope.* 2004 Dec;114(12):2085-91. [Abstract \(http://www.ncbi.nlm.nih.gov/pubmed/15564826?tool=bestpractice.bmj.com\)](http://www.ncbi.nlm.nih.gov/pubmed/15564826?tool=bestpractice.bmj.com)
77. Postema RJ, Kingma CM, Wit HP, et al. Intratympanic gentamicin therapy for control of vertigo in unilateral Ménière's disease: a prospective, double-blind, randomized, placebo-controlled trial. *Acta Otolaryngol.* 2008 Aug;128(8):876-80. [Abstract \(http://www.ncbi.nlm.nih.gov/pubmed/18607963?tool=bestpractice.bmj.com\)](http://www.ncbi.nlm.nih.gov/pubmed/18607963?tool=bestpractice.bmj.com)
78. Webster KE, Lee A, Galbraith K, et al. Intratympanic corticosteroids for Ménière's disease. *Cochrane Database Syst Rev.* 2023 Feb 27;2(2):CD015245. [Full text \(https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015245.pub2/full\)](https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015245.pub2/full) [Abstract \(http://www.ncbi.nlm.nih.gov/pubmed/36847608?tool=bestpractice.bmj.com\)](http://www.ncbi.nlm.nih.gov/pubmed/36847608?tool=bestpractice.bmj.com)
79. Webster KE, Galbraith K, Lee A, et al. Intratympanic gentamicin for Ménière's disease. *Cochrane Database Syst Rev.* 2023 Feb 27;2(2):CD015246. [Full text \(https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015246.pub2/full\)](https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015246.pub2/full) [Abstract \(http://www.ncbi.nlm.nih.gov/pubmed/36847592?tool=bestpractice.bmj.com\)](http://www.ncbi.nlm.nih.gov/pubmed/36847592?tool=bestpractice.bmj.com)
80. Gates GA, Verrall A, Green JD Jr, et al. Meniett clinical trial: long-term follow-up. *Arch Otolaryngol Head Neck Surg.* 2006 Dec;132(12):1311-6. [Full text \(https://jamanetwork.com/journals/jamaotolaryngology/fullarticle/484604\)](https://jamanetwork.com/journals/jamaotolaryngology/fullarticle/484604) [Abstract \(http://www.ncbi.nlm.nih.gov/pubmed/17178941?tool=bestpractice.bmj.com\)](http://www.ncbi.nlm.nih.gov/pubmed/17178941?tool=bestpractice.bmj.com)
81. Thomsen J, Sass K, Odkvist L, et al. Local overpressure treatment reduces vestibular symptoms in patients with Meniere's disease: a clinical, randomized, multicenter, double-blind, placebo-controlled study. *Otol Neurotol.* 2005 Jan;26(1):68-73. [Abstract \(http://www.ncbi.nlm.nih.gov/pubmed/15699722?tool=bestpractice.bmj.com\)](http://www.ncbi.nlm.nih.gov/pubmed/15699722?tool=bestpractice.bmj.com)
82. van Sonsbeek S, Pullens B, van Benthem PP. Positive pressure therapy for Ménière's disease or syndrome. *Cochrane Database Syst Rev.* 2015 Mar 10;(3):CD008419. [Full text \(https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008419.pub2/full\)](https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008419.pub2/full) [Abstract \(http://www.ncbi.nlm.nih.gov/pubmed/25756795?tool=bestpractice.bmj.com\)](http://www.ncbi.nlm.nih.gov/pubmed/25756795?tool=bestpractice.bmj.com)
83. Webster KE, George B, Galbraith K, et al. Positive pressure therapy for Ménière's disease. *Cochrane Database Syst Rev.* 2023 Feb 23;2(2):CD015248. [Full text \(https://www.cochranelibrary.com/\)](https://www.cochranelibrary.com/)

- [cdsr/doi/10.1002/14651858.CD015248.pub2/full](https://doi.org/10.1002/14651858.CD015248.pub2/full) Abstract (<http://www.ncbi.nlm.nih.gov/pubmed/36815713?tool=bestpractice.bmj.com>)
84. Bretlau P, Thomsen J, Tos M, et al. Placebo effect in surgery for Meniere's disease: nine-year follow-up. *Am J Otol*. 1989 Jul;10(4):259-61. Abstract (<http://www.ncbi.nlm.nih.gov/pubmed/2679115?tool=bestpractice.bmj.com>)
 85. Pillsbury HC, Arenberg IK, Ferraro J, et al. Endolymphatic sac surgery. The Danish sham surgery study: an alternative analysis. *Otolaryngol Clin North Am*. 1983 Feb;16(1):123-7.
 86. Thomsen J, Bretlau P, Tos M, et al. Ménière's disease: endolymphatic sac decompression compared with sham (placebo) decompression. *Ann N Y Acad Sci*. 1981 Nov;374(1):820-30. Abstract (<http://www.ncbi.nlm.nih.gov/pubmed/7041752?tool=bestpractice.bmj.com>)
 87. Thomsen J, Bonding P, Becker B, et al. The non-specific effect of endolymphatic sac surgery in treatment of Meniere's disease: a prospective, randomized controlled study comparing "classic" endolymphatic sac surgery with the insertion of a ventilating tube in the tympanic membrane. *Acta Otolaryngol*. 1998 Nov;118(6):769-73. Abstract (<http://www.ncbi.nlm.nih.gov/pubmed/9870617?tool=bestpractice.bmj.com>)
 88. Pullens B, Verschuur HP, van Benthem PP. Surgery for Ménière's disease. *Cochrane Database Syst Rev*. 2013 Feb 28;(2):CD005395. Full text (<https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005395.pub3/full>) Abstract (<http://www.ncbi.nlm.nih.gov/pubmed/23450562?tool=bestpractice.bmj.com>)
 89. Szott FA, Westhofen M, Hackenberg S. Is endolymphatic sac surgery an efficient treatment of Ménière's disease patients? A systematic literature search and meta-analysis. *Eur Arch Otorhinolaryngol*. 2023 Mar;280(3):1119-28. Full text (<https://link.springer.com/article/10.1007/s00405-022-07580-8>) Abstract (<http://www.ncbi.nlm.nih.gov/pubmed/36208333?tool=bestpractice.bmj.com>)
 90. McDonnell MN, Hillier SL. Vestibular rehabilitation for unilateral peripheral vestibular dysfunction. *Cochrane Database Syst Rev*. 2015 Jan 13;(1):CD005397. Full text (<https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005397.pub4/full>) Abstract (<http://www.ncbi.nlm.nih.gov/pubmed/25581507?tool=bestpractice.bmj.com>)
 91. Hansson EE. Vestibular rehabilitation: for whom and how? A systematic review. *Adv Physiother*. 2007;9(3):106-16.
 92. Gottshall KR, Hoffer ME, Moore RJ, et al. The role of vestibular rehabilitation in the treatment of Meniere's disease. *Otolaryngol Head Neck Surg*. 2005 Sep;133(3):326-8. Abstract (<http://www.ncbi.nlm.nih.gov/pubmed/16143175?tool=bestpractice.bmj.com>)
 93. Paparella MM, Sajjadi H. Endolymphatic sac enhancement. Principles of diagnosis and treatment. *Am J Otol*. 1987 Jul;8(4):294-300. Abstract (<http://www.ncbi.nlm.nih.gov/pubmed/3631235?tool=bestpractice.bmj.com>)

94. Silverstein H, Jackson LE. Vestibular nerve section. *Otolaryngol Clin North Am*. 2002 Jun;35(3):655-73. [Abstract \(http://www.ncbi.nlm.nih.gov/pubmed/12486846?tool=bestpractice.bmj.com\)](http://www.ncbi.nlm.nih.gov/pubmed/12486846?tool=bestpractice.bmj.com)
95. Møller MN, Cayé-Tomasen P, Thomsen JH. Vestibular nerve section in the treatment of morbus Ménière [in Danish]. *Ugeskr Laeger*. 2009 Mar 16;171(12):1000-3. [Abstract \(http://www.ncbi.nlm.nih.gov/pubmed/19284921?tool=bestpractice.bmj.com\)](http://www.ncbi.nlm.nih.gov/pubmed/19284921?tool=bestpractice.bmj.com)
96. Berryhill WE, Graham MD. Chemical and physical labyrinthectomy for Meniere's disease. *Otolaryngol Clin North Am*. 2002 Jun;35(3):675-82. [Abstract \(http://www.ncbi.nlm.nih.gov/pubmed/12486847?tool=bestpractice.bmj.com\)](http://www.ncbi.nlm.nih.gov/pubmed/12486847?tool=bestpractice.bmj.com)
97. Graham MD, Colton JJ. Transmastoid labyrinthectomy indications. Technique and early postoperative results. *Laryngoscope*. 1980 Aug;90(8 Pt 1):1253-62. [Abstract \(http://www.ncbi.nlm.nih.gov/pubmed/7401826?tool=bestpractice.bmj.com\)](http://www.ncbi.nlm.nih.gov/pubmed/7401826?tool=bestpractice.bmj.com)
98. Lustig LR, Yeagle J, Niparko JK, et al. Cochlear implantation in patients with bilateral Ménière's syndrome. *Otol Neurotol*. 2003 May;24(3):397-403. [Abstract \(http://www.ncbi.nlm.nih.gov/pubmed/12806291?tool=bestpractice.bmj.com\)](http://www.ncbi.nlm.nih.gov/pubmed/12806291?tool=bestpractice.bmj.com)
99. Pothula VB, Chew F, Lesser TH, et al. Falls and vestibular impairment. *Clin Otolaryngol Allied Sci*. 2004 Apr;29(2):179-82. [Abstract \(http://www.ncbi.nlm.nih.gov/pubmed/15113307?tool=bestpractice.bmj.com\)](http://www.ncbi.nlm.nih.gov/pubmed/15113307?tool=bestpractice.bmj.com)

Images




Figure 1: Pure-tone audiometry typical of Meniere disease

From the collection of Maurice H. Miller, PhD

Disclaimer

BMJ Best Practice is intended for licensed medical professionals. BMJ Publishing Group Ltd (BMJ) does not advocate or endorse the use of any drug or therapy contained within this publication nor does it diagnose patients. As a medical professional you retain full responsibility for the care and treatment of your patients and you should use your own clinical judgement and expertise when using this product.

This content is not intended to cover all possible diagnosis methods, treatments, follow up, drugs and any contraindications or side effects. In addition, since such standards and practices in medicine change as new data become available, you should consult a variety of sources. We strongly recommend that you independently verify specified diagnosis, treatments and follow-up and ensure it is appropriate for your patient within your region. In addition, with respect to prescription medication, you are advised to check the product information sheet accompanying each drug to verify conditions of use and identify any changes in dosage schedule or contraindications, particularly if the drug to be administered is new, infrequently used, or has a narrow therapeutic range. You must always check that drugs referenced are licensed for the specified use and at the specified doses in your region.

Information included in BMJ Best Practice is provided on an “as is” basis without any representations, conditions or warranties that it is accurate and up to date. BMJ and its licensors and licensees assume no responsibility for any aspect of treatment administered to any patients with the aid of this information. To the fullest extent permitted by law, BMJ and its licensors and licensees shall not incur any liability, including without limitation, liability for damages, arising from the content. All conditions, warranties and other terms which might otherwise be implied by the law including, without limitation, the warranties of satisfactory quality, fitness for a particular purpose, use of reasonable care and skill and non-infringement of proprietary rights are excluded.

Where BMJ Best Practice has been translated into a language other than English, BMJ does not warrant the accuracy and reliability of the translations or the content provided by third parties (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages). BMJ is not responsible for any errors and omissions arising from translation and adaptation or otherwise. Where BMJ Best Practice lists drug names, it does so by recommended International Nonproprietary Names (rINNs) only. It is possible that certain drug formularies might refer to the same drugs using different names.

Please note that recommended formulations and doses may differ between drug databases drug names and brands, drug formularies, or locations. A local drug formulary should always be consulted for full prescribing information.

Treatment recommendations in BMJ Best Practice are specific to patient groups. Care is advised when selecting the integrated drug formulary as some treatment recommendations are for adults only, and external links to a paediatric formulary do not necessarily advocate use in children (and vice-versa). Always check that you have selected the correct drug formulary for your patient.

Where your version of BMJ Best Practice does not integrate with a local drug formulary, you should consult a local pharmaceutical database for comprehensive drug information including contraindications, drug interactions, and alternative dosing before prescribing.

Interpretation of numbers

Regardless of the language in which the content is displayed, numerals are displayed according to the original English-language numerical separator standard. For example 4 digit numbers shall not include a comma nor a decimal point; numbers of 5 or more digits shall include commas; and numbers stated to be less than 1 shall be depicted using decimal points. See Figure 1 below for an explanatory table.

BMJ accepts no responsibility for misinterpretation of numbers which comply with this stated numerical separator standard.

This approach is in line with the guidance of the [International Bureau of Weights and Measures Service](#).

Figure 1 – BMJ Best Practice Numeral Style

5-digit numerals: 10,000

4-digit numerals: 1000

numerals < 1: 0.25

Our full website and application terms and conditions can be found here: [Website Terms and Conditions](#).

Contact us

+ 44 (0) 207 111 1105

support@bmj.com

BMJ

BMA House

Tavistock Square

London

WC1H 9JR

UK

BMJ Best Practice

Contributors:

// Authors:

Soha N. Ghossaini, MD, FACS

Otology-Neurotology

Ear Nose and Throat Associates of New York, New York, NY

DISCLOSURES: SNG declares that she has no competing interests.

// Acknowledgements:

Dr Ghossaini would like to gratefully acknowledge the late Professor Maurice H. Miller, a previous contributor to this topic. MHM declared that he had no competing interests.

// Peer Reviewers:

Steven D. Rauch, MD

Associate Professor of Otology and Laryngology

Harvard Medical School, Boston, MA

DISCLOSURES: SDR declares that he has no competing interests.

Christopher J. Linstrom, MD

Professor

Otolaryngology/Head and Neck Surgery, The New York Eye and Ear Infirmary, Surgeon Director, New York, NY

DISCLOSURES: CJL declares that he has no competing interests.

Peter Rea, MA, BM BCh, FRCS(ORL-HNS)

Consultant ENT Surgeon

Leicester Royal Infirmary, Leicester, UK

DISCLOSURES: PR declares that he has no competing interests.

Doris Eva Bamiou, MD, MSc, PhD

Clinical Senior Lecturer & Consultant in Audiovestibular Medicine

Ear Institute, University College London, London, UK

DISCLOSURES: DEB declares that she has no competing interests.